13515-95-2

Basic information

• Product Name: methyl 2,6-diaminohexanoate hydrochloride
• Synonyms: methyl 2,6-diaminohexanoate hydrochloride;(S)-Methyl 2,6-diaminohexanoate hydrochloride
• CAS NO: 13515-95-2
• Molecular Formula: C₇H₁₇N₂O₂*Cl
• Molecular Weight: 196.67508
• Mol File: 13515-95-2.mol
• Article Data: 31

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: methyl 2,6-diaminohexanoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,6-diaminohexanoate hydrochloride(13515-95-2)
• EPA Substance Registry System: methyl 2,6-diaminohexanoate hydrochloride(13515-95-2)

Safety Data

• Hazardous Substances Data: 13515-95-2(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 56-87-1 L-lysine 
• 657-27-2 L-Lysine hydrochloride 
• 77-76-9 2,2-dimethoxy-propane 
• 75-77-4 chloro-trimethyl-silane 
• 70-53-1 2,6-diaminohexanoic acid hydrochloride 
• 26124-78-7 (S)-α-lysine hydrochloride 
• 13734-28-6 Boc-Lys-OH 
• 17929-90-7 3-aminoazepan-2-one 

Downstream Products

• 62056-78-4 C₃₁H₃₄N₂O₄P₂ 
• 21568-87-6 2-aminocaprolactam 
• 2483-48-9 (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester 
• 897932-08-0 (S)-2,6-Bis-(3,4-bis-methoxycarbonyloxy-benzoylamino)-hexanoic acid methyl ester 
• 897932-09-1 (S)-2,6-Bis-(3,4,5-tris-methoxycarbonyloxy-benzoylamino)-hexanoic acid methyl ester 
• 943443-86-5 C₂₂H₃₃N₄O₆ 
• 1184820-62-9 (S)-lysine methyl ester dihydrochloride 
• 1197285-78-1 (S)-2-{(2R,3R,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1337555-97-1 (S)-2-{(2R,3S,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1337556-02-1 (S)-2-{(2S,3S,Z)-1-[(S)-2-benzamido-6-guanidinohexanoyl]-4-ethylidene-3-methylpyrrolidine-2-carboxamido}-4-methyl-pentanoic acid 
• 1360186-70-4 (S)-methyl 2-((2S,3R,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 
• 1360186-73-7 (S)-methyl 2-((2S,3S,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methyl pentanoate 
• 1360186-75-9 (S)-methyl 2-((2R,3S,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 
• 1360186-79-3 (S)-methyl 2-((2R,3R,Z)-1-((S)-2-benzamido-6-((Z)-2,3-bis(tert-butoxycarbonyl)guanidino)hexanoyl)-4-ethylidene-3-methylpyrrolidine-2-carboxamido)-4-methylpentanoate 

Relevant articles and documents

Synthesis, characterization and topical application of novel bifunctional peptide metallodendrimer

Present research work focuses on the synthesis of lower generation bifunctional peptide metallodendrimer followed by its characterization using IR, Mass and NMR (1H and 13C) and finally exploring it for treating acne and wounds. Metallodendrimer was formulated into Tamarind Seed Polysaccharide (TSP) based hydrogel at 7% w/w concentration and analyzed for its properties of spreadability and bioadhesion. Testing of in-vitro antibacterial activity, sterility, in-vivo wound healing efficacy and stability studies followed the formulation development stage. The explored peptide metallodendrimer is a complex of second generation lysine dendrimers and zinc, exhibiting antibacterial activity against Propionibacterium acne, Staphylococcus epidermidis, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. In-vivo wound healing studies in comparison with marketed product indicated significant performance by metallodendrimer with respect to percent re-epithelization and wound contracture. The results were supported by concurrent improvement in various histopathological parameters such as cellularity, granulation, epithelization, vascular density, collagen staining intensity with less number of average mast cells and absence of scar formation. A bifunctional peptide metallodendrimer based platform technology was fabricated and duly evaluated for potential activities.

NOVEL DRUG DELIVERY CONJUGATED MOIETY FOR ORAL ADMINISTRATION OF DRUG UNSUITABLE FOR ORAL ADMINISTRATION AND PREPARATION METHOD THEREOF

The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof is combined with a drug, which is not suitable for oral administration, and is administered orally, it exhibits an excellent absorption rate without decreasing the biological activities of the drug. Moreover, the drug delivery conjugated moiety of the present invention or a pharmaceutically acceptable salt thereof can be easily prepared in a few steps, which is very advantageous in terms of mass production.

Novel chiral derivatizing agents for 1H NMR determination of enantiomeric purities of carboxylic acids

(S)-4-(3-Aminopyrrolidin-1-yl)coumarin (1), (S)-4-(3-aminopiperidin-1-yl)coumarin (4), and (S)-4-(3-aminoazepan-1-yl)coumarin (7), prepared from 4-chlorocoumarin and (S)-pyrrolidin-3-amine, (S)-piperidin-3-amine, and (S)-azepan-3-amine, respectively, were proven to be versatile and reliable 1H NMR optical purity determination agents for chiral carboxylic acids.